Serum IL-6 as a prognostic biomarker and IL-6R as a therapeutic target in biliary tract cancers.

CONCLUSIONS: Serum IL-6 and YKL-40 are potential new prognostic biomarkers in BTC. IL-6 provides independent prognostic information and may be superior to CA19-9 in certain contexts. Moreover, anti-IL-6R should be considered as a new treatment option to sustain gemcitabine response in BTC patients.
PMID: 32933994 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 14, 2020 Category: Cancer & Oncology Authors: Hogdall DTS, O'Rourke CJ, Dehlendorff C, Larsen FO, Jensen LH, Johansen AZ, Dang H, Factor VM, Grunnet M, Mau-Sørensen M, Oliveira DVNP, Linnemann D, Boisen MK, Wang XW, Johansen JS, Andersen JB Tags: Clin Cancer Res Source Type: research